We have previously reported a Candida krusei outbreak during which a number of our patients were infected or colonized by several different closely related Candida krusei genotypes. The treatment response in many of our patients was at best modest and the patients remained positive for Candida krusei . We speculated that extended exposure to antifungals in patients with an incomplete treatment response might lead to the conditions for selection of drug resistance in the multiple Candida krusei clones. Therefore, we followed the in vitro susceptibility of the Candida krusei isolates taken from our patients before and during the antifungal treatment. A total of 28 Candida krusei isolates from 11 patients with prolonged exposure to antifungal medication were analyzed for their in vitro susceptibility to commonly used drugs. We found that MIC 50 values of all Candida krusei isolates was 12 μg/ml for fl uconazole, 0.19 μg/ml for voriconazole, 1.0 μg/ml for amphotericin B, and 1.0 μg/ml for caspofungin with the corresponding MIC 90 values being 16 μg/ml, 0.5 μg/ml, 2.0 μg/ml, and 1.0 μg/ml, respectively. Extended antifungal exposure did not change these MIC values. We conclude that resistance development in Candida krusei during prolonged antifungal treatment may not be common and the treatment failure of our patients was not likely due to the development of drug resistance by the etiologic agent.
Introduction
A change in the epidemiology of invasive Candida infections has been documented in some hospitals with escalating number of cases being caused by Candida glabrata and Candida krusei isolates that are resistant to fl uconazole [1] [2] [3] . Infections caused by species of Candida other than Candida albicans are accompanied by complications and prolonged hospitalization [ 4 ] . In particular, the outcome of invasive Candida krusei infections is often associated with high rates of complications and mortality [ 5 ] . In addition, cases have been described to appear in clusters the origin of which is not completely infections or colonization were widely exposed to antifungal drugs [ 7 ] . We followed the in vitro susceptibility of the Candida krusei isolates before and during the treatment of patients in whom the chosen therapy was unable to cure the infection or prevent the colonization. Our goal was to determine if prolonged antifungal exposure could alter the susceptibility of the Candida krusei isolates.
Patients and setting
As described previously, a cluster of patients with Candida krusei infection or colonization was recognized in the haematological unit of Oulu University Hospital (Oulu, Finland) in 2005 [ 7 ] . The genetic analysis of the isolates showed that each patient was infected or colonized by several closely related Candida krusei genotypes. The patients who failed to be cured of their infections or colonization during the course of antifungal treatment were included in this study.
Microbiological methods
Candida species were isolated from clinical samples on Sabouraud dextrose agar and identifi ed to species level by typical microscopic morphology on Corn Meal agar (Becton, Dickinson & Co., Maryland, USA) and assimilation patterns obtained with ID 32C strips (bioMeriéux sa, Marcy l'Etoile, France). In vitro antifungal susceptibility tests against fl uconazole, voriconazole, amphotericin B, and caspofungin were performed with E-test (AB Biodisk, Solna, Sweden) on agar plates containing RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) and MOPS buffer (Sigma-Aldrich), 2% glucose and 1.5% Bacto agar (Becton Dickinson, Sparks, MD, USA) according to the manufacturer's instructions (Technical guide No. 4, AB Biodisk) and EUCAST guidelines [ 15 ] . The isolates were defi ned as being susceptible if the MIC values were Ͻ1.0 μg/ml for amphotericin B and voriconazole, or Ͻ2.0 μg/ml for caspofungin based on national consensus in Finnish laboratories although no established European recommendations for Candida krusei are available at the moment [ 15 ,16 ] . These values are in agreement with a recent proposal for interpretive MIC breakpoints [ 17 ] .
Genetic analysis of the Candida krusei isolates was performed using a pulsed-fi eld electrophoresis method as described in our outbreak report [ 7 ] . The previous analysis included six isolates of the current study (isolates 1, 4-6, 18, and 19) . In addition, patients 1 to 8 and patient 11 of the current study were shown to be infected or colonized by several different closely related Candida krusei genotypes in our previous genetic analysis [ 7 ] .
Case reports
Patient 1 . A 32-year-old female with acute myeloid leukemia (AML) developed neutropenic fever after the start of induction therapy. Fluconazole (400 mg per day) prophylaxis was replaced with caspofungin (the caspofungin dose in all patients was a 70 mg loading dose followed by 50 mg per day) due to the development of a C. krusei bloodstream infection (BSI) ( Table 1 , isolate 1). The central venous catheters were removed and voriconazole (the voriconazole dose in all patients was initiated with a 400 mg bid loading dose followed by 200 mg bid) was added six days later because of persisting high fever. The patient received her second induction treatment with continued caspofungin and voriconazole treatment during which she developed skin abscesses that were found to be caused by the same etiologic agent ( Table 1 , isolate 2). The abscesses were still positive for C. krusei after the patient had received antifungal treatment for over two months ( Table 1 , isolate 3). During her second consolidation therapy fi ve months later, the patient developed hepatosplenic candidiasis (biopsies were not taken) that was successfully treated with conventional amphotericin B (0.7 mg/kg) and caspofungin.
Patient 2.
A 71-year-old male required a gastrojejunostomy and external drainage of the biliary tree because of a duodenal adenocarcinoma. He received fl uconazole and liposomal amphotericin B (3 mg/kg) to treat a C. krusei BSI ( Table 1 , isolate 4). Two weeks later, his external biliary drainage continued to be positive for C. krusei while on amphotericin B treatment ( Table 1 , 
isolate 5).
Patient 3. A 46-year-old-female patient with systemic mastocytosis received fl uconazole (400 mg) for esophagitis during neutropenic fever followed by C. krusei BSI ( Table  1 , isolate 6). She was treated with voriconazole, but developed a skin abscess in her elbow region two weeks later that proved positive for C. krusei growth ( Table 1 , isolate 7). Ten days later an abscess of the parotid gland ( Candida krusei positive) was recognized. The condition was fi nally successfully treated with voriconazole monotherapy which lasted for total of six weeks.
Patient 4.
A 53-year-old female suffered a second relapse of AML and developed neutropenic fever while on prophylactic fl uconazole therapy (400 mg) after the induction treatment. Candida krusei was isolated from her pharynx and rectum one week later ( Table 1 , isolates 8 and 9), with fl uconazole being replaced with caspofungin because of persistent neutropenic fever. She developed severe enteritis and septic shock requiring surgical intervention. Liposomal amphotericin B (3 mg/kg/day) was combined because her ascites fl uid was positive for C. krusei ( Table 1 , isolate 10). In spite of the intensive treatment, she developed multiorgan failure and died. Invasive abdominal C. krusei growth was found at post-mortem (susceptibility testing not available).
Patient 5.
A 39-year-old previously healthy male suffered a sudden onset of HSV encephalitis and C. albicans BSI which required intensive care unit treatment for two months. He received liposomal amphotericin B (3 mg/kg) followed by combinations caspofungin and fl uconazole or caspofungin and voriconazole for two months after which he continued on voriconazole (200 mg po bid) for four months until his unexpected death. An invasive C. krusei infection was found in the abdomen at post-mortem ( Table 1 , isolate 11). The patient was most likely suffering from a primary immunodefi ciency which is still under investigation. Table 1 The table shows MIC (g/ml) values of the Candida krusei isolates collected from the patients described in the case reports. The date and the anatomical location from which the clone was isolated is indicated. Antifungal treatment (fl u = fl uconazole, vori = voriconazole, amB = amphotericin B, cas = caspofungin, none = no antifungal treatment) and the cumulative number of days (d) of drug exposure before sampling is indicated. The asterisk (*) indicates the antifungal drug that was being administered when the sample was taken. n. 
Results
MIC 50 values of all C. krusei isolates were 12 μg/ml for fl uconazole, 0.19 μg/ml for voriconazole, 1.0 μg/ml for amphotericin B, and 1.0 μgt/ml for caspofungin and the MIC 90 values were 16 μg/ml, 0.5 μg/l, 2.0 μg/ml, and 1.0 μg/ml, respectively. Despite the signifi cant exposure to antifungal agents, the in vitro susceptibility of our isolates remained unaffected ( Table 1 ) .
Discussion
Treatment failure in invasive fungal infection is common due to the properties of the host and/or the pathogen [ 4 ,18 , 19 ] . In our patients, the response to a wide variety of treatment alternatives was at best modest and C. krusei infection or colonization persisted during or after antifungal monotherapy or even combinations of drugs. Despite the extensive exposure to antifungal agents combined with the poor state of the host, which should have offered ideal conditions for the development of resistance, the MIC values remained unchanged during the treatment. Most likely, the poor recovery of the immune system accounts for the inadequate response to these medications in our cases.
Pfaller and co-workers reported that voriconazole resistant C. krusei isolates could be found in several countries [ 14 ] . In our patients, isolates of C. krusei with low MIC values were recovered from skin abscesses, the kidney, and rectal mucosa during and after signifi cant voriconazole exposure. Caspofungin resistance of C. krusei was described in a recently published case in which the fungus was isolated from mucosal samples [ 11 ] . Some of our patients received caspofungin or other antifungals for several weeks and C. krusei isolates from mucosal samples remained susceptible during or after the treatment. In summary, during active antifungal treatment C. krusei clones with unchanged susceptibility were isolated from the lungs, kidneys, ascites, skin abscesses, external drainage of biliary tract, and mucosa of the rectum or pharynx. It is possible that drug concentrations at these anatomical locations were too low to eradicate the the fungus. Penetration of voriconazole into these sites in humans is not well established and our understanding of distribution of other antifungals is incomplete [ 20 ] . It is possible that the low drug concentration in the target tissues may play a critical role in killing these fungi and to some degree explain our results. A suboptimal drug concentration for an extended time, however, should have created favorable conditions for the development of resistance. In addition, the presence of foreign bodies such as drainage of the biliary tract or central venous catheters in our patients should also have favored the potential for resistance because of neutropenic fever after consolidation therapy for AML. C. krusei was found in his rectal and pharyngeal swabs during ( Patient 11. A 32-year-old female with AML started to undergo her fi rst course of consolidation treatment and was found to be colonized by C. krusei in the pharynx and rectum ( Table 1 , isolate 25). She initially received conventional amphotericin B (0.7 mg/kg/day) for persistent neutropenic fever followed by caspofungin empirically for two weeks. She continued to be intensively colonized with the same fungus despite the continued caspofungin treatment ( Table 1 , isolates 26-28).
development. On the other hand, one would expect the caspofungin concentration to be relatively high in the kidney [ 20 ] but nonetheless, a susceptible C. krusei isolate was found in a kidney specimen of our patient. Repeated exposure of our patients to drug susceptible C. krusei during the outbreak is another potential explanation for our results. Our infection control measures, however, were stringent once the outbreak was recognized and we were not able to demonstrate spread of a single Candida krusei strain among our patients or the health care workers [ 7 ] .
Susceptibility testing of the antifungal drugs on our samples was carried out by the E-test which has been shown to be a reliable alternative compared to the broth microdilution method [ 21, 22 ] . The MIC breakpoint values defi ning susceptibility for voriconazole, amphotericin B, or caspofungin have not been defi nitely established for C. krusei [ 15 ] . The MIC values for caspofungin in our isolates were slightly higher compared to those obtained from some wild type isolates. The values were, however, within the limits that are generally considered to correlate with susceptibility [ 14 ,17 ] . The susceptibility testing of Candida isolates with mutations in the 1-3--D-glucan synthase gene, for example, has demonstrated significantly higher MIC values for caspofungin [ 23 ] . Our results suggest that the occurrence of underlying drug resistant C. krusei clones is rare. Overgrowth of such drug resistant clones should have been possible under these conditions of selection pressure evoked by the treatment. We conclude that in vitro resistance does not seem to commonly develop in isolates from patients who fail to respond to appropriate or suboptimal antifungal treatment for Candida krusei .
